Evidence map›Paper›PMID 25398832›Full record

Trial reportHaematologica2015

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Philippe Rodon, Cyrille Hulin, Brigitte Pegourie, Mourad Tiab, Bruno Anglaret, Lotfi Benboubker, Henry Jardel, Olivier Decaux, Brigitte Kolb, Murielle Roussel and 20 more

Open access · goldAbstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. The Diagnosis and Treatment of Multiple Myeloma.Deutsches Arzteblatt international · 2016
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Novel Agents in Multiple Myeloma.Cancer journal (Sudbury, Mass.)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 4 countries.

Philippe RodonHospital Center, Périgueux rodon.philippe@wanadoo.fr.
Cyrille HulinUniversity Hospital, Nancy.
Brigitte PegourieUniversity Hospital, Grenoble, France.
Mourad TiabHospital Center, La Roche sur Yon, France.
Bruno AnglaretHospital Center, Valence.
Lotfi BenboubkerUniversity Hospital, Tours.
Henry JardelHospital Center, Vannes.
Olivier DecauxUniversity Hospital, Rennes.
Brigitte KolbUniversity Hospital, Reims.
Murielle RousselUniversity Hospital, Toulouse.
Laurent GarderetHôpital St Antoine, Assistance Publique-Hôpitaux de Paris, Paris.
Xavier LeleuUniversity Hospital, Lille.
Olivier FitoussiPolyclinique Nord-Aquitaine, Bordeaux.
Carine ChaleteixUniversity Hospital, Clermont-Ferrand.
Philippe CasassusHôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny.
Pascal LenainCentre de Lutte contre le Cancer Rouen, France.
Bruno RoyerUniversity Hospital, Amiens.
Anne BanosHospital Center, Bayonne.
Riad BenramdaneHospital Center, Pontoise.
Pascale Cony-MakhoulHospital Center, Annecy.
Mamoun DibUniversity Hospital, Angers.
Jean FontanUniversity Hospital, Besançon.
Anne-Marie StoppaInstitut Paoli Calmette, Marseille.
Catherine TraulléUniversity Hospital, Lyon.
Jean-Pierre VilqueCentre François Baclesse, Caen.
Marie-Odile PétillonUniversity Hospital, Lille.
Claire MathiotInstitut Curie, Paris.
Thomas DejoieUniversity Hospital, Nantes, France.
Hervé Avet-LoiseauUniversity Hospital, Toulouse.
Philippe MoreauUniversity Hospital, Nantes, France.
Assistance Publique – Hôpitaux de Paris · FRCentre François Baclesse · LUCentre hospitalier Bretagne Atlantique · FRCentre Hospitalier de la Côte Basque · FRCentre Hospitalier de Valence · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire Amiens-Picardie · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Reims · FRGefluc Languedoc Roussillon · FRInstitut Curie · FRInstitut Paoli-Calmettes · FRLyon College · USPolyclinique Bordeaux Nord Aquitaine · FRRoche (France) · FRUniversité d'Angers · FRUniversité de Tours · FRUniversité Grenoble Alpes · FRUniversity Hospital Waterford · IE

Funding

Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5M
NCI NIH HHS P01 CA155258
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBoronic AcidsBortezomibDexamethasoneFemaleFollow-Up StudiesHumansMaleMultiple MyelomaNeoplasm GradingNeoplasm Recurrence, LocalNitrogen Mustard CompoundsPrognosisBendamustine HydrochlorideBoronic AcidsBortezomibDexamethasoneNitrogen Mustard CompoundsPyrazinesbendamustineelderlymultiple myelomarelapse

Identifiers

PMID25398832
PMCPMC4803137
OpenAlexW2059895867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.